: Usana sees sales bump in China, but 2023 still uncertain

Usana Health Sciences Inc. falls more than 4% in the extended session Thursday after the multi-level marketing company calls for lower 2023 sales and profit than Wall Street expected, saying it is unsure whether an uptick in sales at the end of 2022 will last.

Previous post : Bed Bath & Beyond planning to file for bankruptcy: report
Next post Crypto: What is BONK, and why is its price up 3,174% this week?